Jennifer Kayden Lee insider trades: Rhythm Pharmaceuticals (RYTM) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Jennifer reports to the SEC
Open-market buys and sales
19 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Aug 13, 2026 | RYTM | ↓ Sell | 75,834 | $117.38 | $8.9M | Direct | Aug 14, 2026 (1d) |
| Feb 19, 2025 | RYTM | ↓ Sell | 2,035 | $57.22 | $116K | Direct | Feb 19, 2025 (0d) |
| Feb 13, 2025 | RYTM | ↓ Sell | 3,020 | $57.03 | $172K | Direct | Feb 14, 2025 (1d) |
| Feb 11, 2025 | RYTM | ↓ Sell | 5,216 | $58.64 | $306K | Direct | Feb 11, 2025 (0d) |
| Feb 5, 2025 | RYTM | ↓ Sell | 3,066 | $60.55 | $186K | Direct | Feb 7, 2025 (2d) |
| Feb 4, 2025 | RYTM | ↓ Sell | 1,447 | $59.43 | $86K | Direct | Feb 4, 2025 (0d) |
| Nov 11, 2024 | RYTM | ↓ Sell | 66,861 | $66.33 | $4.4M | Direct | Nov 13, 2024 (2d) |
| Mar 20, 2024 | RYTM | ↓ Sell | 18,235 | $38.77 | $707K | Direct | Mar 22, 2024 (2d) |
| Mar 19, 2024 | RYTM | ↓ Sell | 15,515 | $39.22 | $608K | Direct | Mar 19, 2024 (0d) |
| Feb 13, 2024 | RYTM | ↓ Sell | 1,638 | $50.80 | $83K | Direct | Feb 13, 2024 (0d) |
| Feb 1, 2024 | RYTM | ↓ Sell | 1,492 | $45.06 | $67K | Direct | Feb 5, 2024 (4d) |
| Nov 14, 2023 | RYTM | ↓ Sell | 13,677 | $32.01 | $438K | Direct | Nov 16, 2023 (2d) |
| Nov 9, 2023 | RYTM | ↓ Sell | 9,150 | $28.45 | $260K | Direct | Nov 13, 2023 (4d) |
| Nov 3, 2023 | RYTM | ↓ Sell | 80 | $28.00 | $2K | Direct | Nov 7, 2023 (4d) |
| Sep 5, 2023 | RYTM | ↓ Sell | 6,166 | $28.05 | $173K | Direct | Sep 7, 2023 (2d) |
| Aug 9, 2023 | RYTM | ↓ Sell | 12,941 | $24.24 | $314K | Direct | Aug 9, 2023 (0d) |
| Feb 14, 2023 | RYTM | ↓ Sell | 635 | $26.87 | $17K | Direct | Feb 14, 2023 (0d) |
| Feb 9, 2023 | RYTM | ↓ Sell | 1,192 | $27.66 | $33K | Direct | Feb 13, 2023 (4d) |
| Feb 15, 2022 | RYTM | ↓ Sell | 722 | $6.10 | $4K | Direct | Feb 15, 2022 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
Other RYTM insiders
Open-market trades in the last 12 months
About Jennifer Kayden Lee's insider trades
Jennifer Kayden Lee is EVP, Head of North America at Rhythm Pharmaceuticals (RYTM). Since Feb 15, 2022, Jennifer has reported no open-market purchases and 19 sales worth $16.9M on SEC Form 4. In the last 12 months: 1 sale ($8.9M).
Their filings also include option exercises (16 filings), grants and awards (8 filings), shares withheld for taxes (1 filing). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every RYTM insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.